This new interactive feature allows you to review the treatment options for low-risk primary myelofibrosis, share your approach to determining the highest value treatment, and help to build a consensus clinical pathway for this disease.


The relationship between transfusion dependency and health-related quality of life in patients with myelodysplastic syndromes may differ based on disease risk at diagnosis.
The hypomethylating agents decitabine and azacitidine administered at a low dose is safe and effective for patients with lower-risk myelodysplastic syndrome and myeloproliferative neoplasms.
Subscribe to Myeloproliferative Neoplasms